fsd1 Antibody

What is FSD1 protein and what is its biological significance?

FSD1 (Fibronectin Type III and SPRY Domain Containing 1) is a 496 amino acid protein with a molecular weight of approximately 55.8 kDa in humans. It functions primarily in microtubule organization and stabilization within cells . FSD1 works in tandem with cytoskeletal proteins like actin and tubulin that are crucial for maintaining cellular morphology and facilitating movement . It forms part of a larger structural complex that contributes to cellular shape maintenance and stability . The protein contains characteristic fibronectin type III and SPRY domains that are important for its functional properties . Understanding FSD1 is particularly relevant in neurological research due to its high expression in brain tissues .

Where is FSD1 protein predominantly expressed in human tissues?

FSD1 demonstrates significant tissue specificity with particularly high expression in brain tissues. Specifically, FSD1 is abundantly expressed in the cerebellum, cerebral cortex, medulla, occipital pole, frontal lobe, temporal lobe, and putamen . This neurological enrichment suggests specialized functions in neural cells and brain architecture. When designing experiments targeting FSD1, researchers should consider these expression patterns, especially when selecting positive control tissues for immunohistochemistry or selecting appropriate cell lines for in vitro studies . Neuroblastoma cell lines such as SK-N-SH and SK-N-AS have been successfully used in FSD1 research as demonstrated in immunocytochemistry and Western blot applications .

What are the key structural characteristics of FSD1 protein?

The human FSD1 protein is characterized by two distinctive domains: a fibronectin type III domain and a SPRY domain . The complete amino acid sequence of the protein consists of 496 residues . The protein is often referred to by several synonyms including MID1-related protein 1, GLFND, MIR1, and VLP27 . The fibronectin type III domain is typically involved in cell adhesion, cell morphology, and cytoskeletal interactions, while the SPRY domain often mediates protein-protein interactions . These structural features directly influence antibody design strategies, with different commercially available antibodies targeting various epitopes throughout the protein sequence, including full-length antibodies (AA 1-496) and those targeting specific regions such as AA 251-370 .

How should I select the appropriate FSD1 antibody for my specific research application?

Selection of an appropriate FSD1 antibody requires consideration of multiple factors including the targeted epitope, host species, clonality, and intended applications. For full protein detection, antibodies targeting the complete sequence (AA 1-496) provide comprehensive coverage . For domain-specific studies, select antibodies that target relevant regions such as AA 251-370 for fibronectin domain studies or AA 421-496 for SPRY domain investigations .

Application compatibility is crucial - some antibodies are validated only for specific techniques. For example, ABIN949636 is validated for Western blotting and immunoprecipitation , while ABIN7152883 is optimized for ELISA and immunohistochemistry . Antibody ab229666 offers broader application flexibility with validation for Western blot, IHC-P, and ICC/IF techniques .

For cross-species studies, verify reactivity patterns. Some antibodies react exclusively with human FSD1 , while others demonstrate cross-reactivity with mouse or rat FSD1 . When conducting multi-species comparative analyses, selecting antibodies with validated cross-reactivity reduces experimental variability.

What are the optimal protocols for detecting FSD1 using immunochemical techniques?

For Western blot applications, optimal detection of FSD1 typically employs 10% SDS-PAGE gels with protein loading of approximately 30 μg of whole cell lysate . Antibody dilutions generally range from 1:1000 to 1:5000 depending on the specific antibody and detection system utilized. Validated cell lines for positive controls include U87-MG (human glioblastoma-astrocytoma), SK-N-SH (human neuroblastoma), IMR32 (human neuroblast), and SK-N-AS (human neuroblastoma) .

For immunocytochemistry, a fixation protocol using 4% paraformaldehyde is recommended, with antibody dilutions typically around 1:500. Nuclear counterstaining with markers such as Hoechst 33342 provides context for subcellular localization studies . When performing immunohistochemistry on paraffin-embedded tissues, antibody dilutions of approximately 1:1200 have been successfully employed for brain tissue sections .

For all applications, blocking and incubation conditions should be optimized according to the specific antibody manufacturer's recommendations. Validation of results through appropriate positive and negative controls is essential for ensuring specificity and reliability of FSD1 detection.

How can I effectively validate the specificity of an FSD1 antibody?

Validating FSD1 antibody specificity requires a multi-faceted approach. Begin with Western blot analysis using lysates from cell lines known to express FSD1, such as neuroblastoma lines SK-N-SH, IMR32, and SK-N-AS, confirming a single band at the expected molecular weight of approximately 55.8 kDa . Compare this with negative control tissues or cell lines with minimal FSD1 expression.

Immunoprecipitation followed by mass spectrometry can provide definitive confirmation of antibody specificity . This approach allows verification that the antibody is capturing the intended target protein rather than cross-reacting with structurally similar proteins.

For immunohistochemistry or immunocytochemistry applications, perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide before tissue application. Disappearance of signal indicates specificity for the target epitope . Additionally, validating results with a second antibody targeting a different epitope of FSD1 can confirm specificity through convergent results.

RNA interference techniques (siRNA or shRNA) to knockdown FSD1 expression followed by immunodetection provides functional validation of antibody specificity, as signal reduction should correlate with reduced protein expression.

What methodologies can elucidate FSD1's role in microtubule organization?

Investigating FSD1's role in microtubule organization requires combined approaches targeting protein-protein interactions and functional cellular assays. Co-immunoprecipitation using FSD1 antibodies (such as ABIN949636 ) can identify binding partners within the microtubule network. This should be followed by immunofluorescence co-localization studies using confocal microscopy to visualize spatial relationships between FSD1 and tubulin or other cytoskeletal components.

Live-cell imaging with fluorescently tagged FSD1 combined with microtubule disruption agents (nocodazole, colchicine) allows temporal assessment of FSD1's contribution to microtubule dynamics. Functional assays measuring microtubule stability in cells with modulated FSD1 expression (overexpression or knockdown) can quantitatively assess the protein's stabilizing effects.

Super-resolution microscopy techniques (STORM, PALM) provide nanoscale visualization of FSD1 localization relative to microtubule structures. For in vitro analyses, purified FSD1 protein can be assessed for direct binding to microtubules through microtubule co-sedimentation assays and surface plasmon resonance to determine binding kinetics and affinity.

How can FSD1 antibodies facilitate neurological disease research?

Given FSD1's high expression in brain tissues (cerebellum, cerebral cortex, medulla, and other regions ), FSD1 antibodies present valuable tools for neurological research. Immunohistochemical analysis using antibodies like ab229666 at 1:1200 dilution allows examination of FSD1 expression patterns across different brain regions in both normal and pathological states .

For neurodevelopmental studies, tracking FSD1 expression during different developmental stages can illuminate its role in neural architecture establishment. Comparative immunostaining between control and disease model tissues (using mouse models or human patient samples) can identify alterations in FSD1 expression or localization associated with specific neurological conditions.

Co-immunoprecipitation studies in neural tissues can reveal FSD1 interaction partners specific to neuronal cells, potentially identifying neurological disease-relevant protein complexes. Cerebrospinal fluid analysis for FSD1 presence using sensitive ELISA assays may provide biomarker potential for certain neurological conditions.

When conducting neurodegenerative disease research, dual immunolabeling for FSD1 and pathological markers (such as amyloid plaques or tau tangles) can reveal spatial relationships between FSD1 and disease-specific features.

What techniques can differentiate between FSD1 isoforms or post-translational modifications?

Distinguishing FSD1 isoforms or post-translational modifications requires specialized approaches beyond standard antibody applications. Two-dimensional gel electrophoresis followed by Western blotting can separate FSD1 variants based on both molecular weight and isoelectric point, revealing charge differences indicative of modifications.

Isoform-specific antibodies targeting unique sequences can be developed through careful epitope selection. For example, antibodies recognizing junctions between exons present in some but not all isoforms provide isoform specificity . Mass spectrometry analysis of immunoprecipitated FSD1 allows precise identification of post-translational modifications including phosphorylation, acetylation, and ubiquitination sites.

Phosphorylation-specific antibodies can be utilized when phosphorylation sites are known. Treatment of samples with phosphatases prior to analysis can confirm phosphorylation-dependent signals. For glycosylation detection, samples can be treated with glycosidases followed by mobility shift analysis on Western blots.

When studying potential sumoylation or ubiquitination, immunoprecipitation with FSD1 antibodies followed by Western blotting with anti-SUMO or anti-ubiquitin antibodies can reveal these modifications. For temporal studies of dynamic modifications, pulse-chase experiments combined with immunoprecipitation at different timepoints enables tracking modification kinetics.

What are common causes of non-specific binding with FSD1 antibodies and how can they be mitigated?

Non-specific binding with FSD1 antibodies can stem from multiple sources. Insufficient blocking is a primary cause - increase blocking agent concentration (typically 5% BSA or 5-10% normal serum from the secondary antibody host species) and extend blocking time to 1-2 hours at room temperature . Secondary antibody cross-reactivity can be addressed by selecting species-adsorbed secondary antibodies specifically tested against tissues being examined.

Excessive antibody concentration often increases background - titrate primary antibodies carefully, starting with manufacturer recommendations (typically 1:500-1:1000 for ICC/IF, 1:1000 for Western blot, and 1:1200 for IHC-P for FSD1 antibodies) . Include appropriate controls including secondary-only controls and isotype controls matched to the primary antibody class and subclass.

For tissue immunohistochemistry, endogenous peroxidase activity can be blocked using hydrogen peroxide treatment prior to antibody application. When working with tissues or cells with high endogenous biotin, use biotin/avidin blocking kits before applying biotinylated reagents. Additional washes with higher salt concentration (up to 500 mM NaCl) in wash buffers can reduce ionic interactions causing non-specific binding.

How can I optimize Western blot detection of FSD1 protein?

Optimizing Western blot detection of FSD1 requires attention to sample preparation, electrophoresis conditions, and detection parameters. Sample preparation should include protease inhibitors to prevent degradation, with 30 μg of total protein typically sufficient for detection in cells with normal expression levels . For cell lines with lower expression, consider using immunoprecipitation to enrich FSD1 prior to Western blotting.

10% SDS-PAGE gels are optimal for resolving the 55.8 kDa FSD1 protein . Transfer conditions should be optimized for proteins in this size range - typically 100V for 60-90 minutes in a wet transfer system or 25V for 30 minutes in semi-dry systems. Membrane blocking with 5% non-fat dry milk or 5% BSA for 1 hour at room temperature reduces background.

Optimal primary antibody dilutions range from 1:1000 to 1:5000 depending on the specific antibody . Neuroblastoma cell lines (SK-N-SH, IMR32, SK-N-AS) and glioblastoma cell lines (U87-MG) serve as positive controls . Include molecular weight markers to confirm the expected 55.8 kDa band size. For enhanced sensitivity, consider using fluorescent secondary antibodies and digital imaging systems or chemiluminescent detection with film exposure times optimized through multiple test exposures.

How can inconsistent results between different detection methods for FSD1 be resolved?

Discrepancies in FSD1 detection between different methods often arise from technique-specific factors. When facing inconsistencies between Western blotting and immunostaining results, consider epitope accessibility differences - some epitopes may be masked in fixed tissues but accessible in denatured Western samples. Try multiple antibodies targeting different regions of FSD1 (e.g., AA 1-496, AA 251-370) .

For differences between immunocytochemistry and immunohistochemistry results, variations in fixation methods significantly impact epitope preservation. Compare results using different fixatives (paraformaldehyde, methanol, acetone) and fixation durations . Cell-specific post-translational modifications may alter epitope recognition between different cell types or tissues - use phosphatase or other enzymatic treatments to investigate this possibility.

When ELISA results differ from other methods, remember that ELISA typically detects soluble proteins, while some FSD1 populations may be tightly associated with cytoskeletal structures. Use different extraction methods (varying detergent types and concentrations) to ensure complete protein solubilization.

Perform antibody validation experiments appropriate to each method being used. For Western blotting, include positive control lysates from neuroblastoma cell lines . For immunostaining, include known positive tissue sections (brain regions) . When possible, complement antibody-based detection with non-antibody methods such as mRNA detection through RT-PCR or RNA-seq to confirm expression patterns.

What emerging technologies might enhance FSD1 research beyond traditional antibody applications?

Next-generation research into FSD1 will benefit from integrating advanced molecular and imaging technologies. CRISPR-Cas9 gene editing enables precise modification of endogenous FSD1, allowing introduction of fluorescent tags for live imaging or creating specific mutations to study domain functions. This approach maintains physiological expression levels, avoiding artifacts associated with overexpression systems.

Proximity labeling techniques such as BioID or APEX2 fused to FSD1 can identify proximal proteins in living cells, providing spatial interaction maps beyond what co-immunoprecipitation can reveal. Single-cell proteomics approaches can examine FSD1 expression heterogeneity across cell populations, particularly relevant in complex tissues like brain where cellular diversity is high.

Cryo-electron microscopy of FSD1-containing complexes can reveal structural details of interactions with cytoskeletal components at near-atomic resolution. Optogenetic approaches with light-inducible FSD1 interactions can enable temporal control over FSD1 function, allowing precise dissection of its role in dynamic cellular processes.

High-content screening approaches using automated microscopy combined with machine learning analysis can quantify subtle phenotypic changes associated with FSD1 modulation across thousands of cells, potentially revealing previously unrecognized functions.

How can quantitative methodologies improve FSD1 expression analysis in different physiological states?

Quantitative approaches to FSD1 analysis require standardized methodologies. Digital pathology using whole slide imaging combined with artificial intelligence-based analysis can quantify FSD1 immunostaining across entire tissue sections, providing spatial distribution data impossible to obtain manually. This approach enables objective comparison between normal and pathological samples.

Multiplex immunofluorescence techniques allow simultaneous detection of FSD1 alongside multiple markers for cell types, cellular compartments, or functional states, providing contextual information about FSD1 expression. Mass cytometry (CyTOF) using metal-conjugated FSD1 antibodies enables simultaneous measurement of dozens of parameters at single-cell resolution.

Absolute quantification of FSD1 protein levels can be achieved through SILAC (Stable Isotope Labeling with Amino acids in Cell culture) or other mass spectrometry-based approaches, providing precise copy numbers per cell across different conditions or tissues. Quantitative PCR or digital droplet PCR for FSD1 mRNA, combined with protein quantification, can reveal regulatory mechanisms at transcriptional versus post-transcriptional levels.

Longitudinal studies using these quantitative approaches can track FSD1 expression changes during development, disease progression, or response to experimental interventions, providing dynamic rather than static assessment of FSD1's role in various physiological and pathological processes.